Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)

ClinicalTrials.gov ID: NCT00903422

Public ClinicalTrials.gov record NCT00903422. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)

Study identification

NCT ID
NCT00903422
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
98 participants

Conditions and interventions

Interventions

  • eltrombopag olamine Drug
  • Placebo Other

Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 13, 2009
Primary completion
Jun 25, 2012
Completion
Dec 4, 2013
Last update posted
Nov 12, 2017

2009 – 2013

United States locations

U.S. sites
24
U.S. states
16
U.S. cities
23
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35294
GSK Investigational Site Santa Monica California 90404
GSK Investigational Site Stanford California 94305
GSK Investigational Site Coral Springs Florida 33065
GSK Investigational Site Lake Worth Florida 33467
GSK Investigational Site Atlanta Georgia 30341
GSK Investigational Site Baltimore Maryland 21231
GSK Investigational Site Boston Massachusetts 02111
GSK Investigational Site Detroit Michigan 48202
GSK Investigational Site Kansas City Missouri 64128
GSK Investigational Site St Louis Missouri 63110
GSK Investigational Site Camden New Jersey 08103
GSK Investigational Site The Bronx New York 10461
GSK Investigational Site Philadelphia Pennsylvania 19104
GSK Investigational Site Philadelphia Pennsylvania 19106
GSK Investigational Site Pittsburgh Pennsylvania 15224
GSK Investigational Site Greenville South Carolina 29601
GSK Investigational Site Memphis Tennessee 38120
GSK Investigational Site Houston Texas 77030
GSK Investigational Site New Braunfels Texas 78130
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site Arlington Virginia 22205
GSK Investigational Site Fairfax Virginia 22031
GSK Investigational Site Madison Wisconsin 53705

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00903422, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 12, 2017 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00903422 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →